Ca2+/calmodulin-dependent protein kinase IIα (αCaMKII) controls the activity of the dopamine transporter: Implications for angelman syndrome

Journal of Biological Chemistry

Volumn 287, Issue 35, 2012, Pages 29627-29635

  Steinkellner, Thomas ^a   Yang, Jae Won ^a   Montgomery, Therese R ^a,b   Chen, Wei Qiang ^a   Winkler, Marie Therese ^a   Sucic, Sonja ^a   Lubec, Gert ^a   Freissmuth, Michael ^a   Elgersma, Ype ^c   Sitte, Harald H ^a   Kudlacek, Oliver ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1-METHYL-4-PHENYLPYRIDINIUM; DOPAMINE TRANSPORTERS; DOPAMINE TRANSPORTS; EXTRACELLULAR; HYPERACTIVITY DISORDER; IN-VITRO; IONIC COMPOSITION; METHYLPHENIDATE; MUTANT MICE; NEURO-GENETIC; PHARMACOLOGICAL INHIBITION; PROTEIN KINASE; PSYCHOSTIMULANT DRUGS; THREONINE KINASE;

AMINO ACIDS; ENZYMES;

MAMMALS;

1 METHYL 4 PHENYLPYRIDINIUM; AMPHETAMINE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE IIALPHA; DOPAMINE TRANSPORTER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SYNAPTOSOME; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC TRANSMISSION; ENZYME ACTIVITY; ENZYME INHIBITION; HAPPY PUPPET SYNDROME; IMMUNOPRECIPITATION; MOUSE; NEUROMODULATION; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT;

AMINO ACID SUBSTITUTION; AMPHETAMINE; ANGELMAN SYNDROME; ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINERGIC NEURONS; HUMANS; MICE; MICE, KNOCKOUT; MUTATION, MISSENSE; NERVE TISSUE PROTEINS; SIGNAL TRANSDUCTION;

MUS;

EID: 84865470520     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.367219     Document Type: Article

References (40)

1. Blakely, R. D., and Bauman, A. L. (2000) Biogenic amine transporters: Regulation in flux. Curr. Opin. Neurobiol. 10, 328-336
2. Kristensen, A. S., Andersen, J., Jørgensen, T. N., Sørensen, L., Eriksen, J., Loland, C. J., Strømgaard, K., and Gether, U. (2011) SLC6 neurotransmitter transporters: Structure, function, and regulation. Pharmacol. Rev. 63, 585-640
3. Ramamoorthy, S., Shippenberg, T. S., and Jayanthi, L. D. (2011) Regulation of monoamine transporters: Role of transporter phosphorylation. Pharmacol. Ther. 129, 220-238
4. Iversen, L. L. (1971) Role of transmitter uptake mechanisms in synaptic neurotransmission. Br J. Pharmacol. 41, 571-591
5. Amara, S. G., and Kuhar, M. J. (1993) Neurotransmitter transporters: Recent progress. Annu. Rev. Neurosci. 16, 73-93
6. Steinkellner, T., Freissmuth, M., Sitte, H. H., and Montgomery, T. (2011) The ugly side of amphetamines: Short and long term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy"), methamphetamine, and D-amphetamine. Biol. Chem. 392, 103-115
7. Fleckenstein, A. E., Volz, T. J., Riddle, E. L., Gibb, J. W., and Hanson, G. R. (2007) New insights into the mechanism of action of amphetamines. Annu. Rev. Pharmacol. Toxicol. 47, 681-698
8. Seiden, L. S., Sabol, K. E., and Ricaurte, G. A. (1993) Amphetamine: Effects on catecholamine systems and behavior. Annu. Rev. Pharmacol. Toxicol. 33, 639-677
9. Sulzer, D., Sonders, M. S., Poulsen, N. W., and Galli, A. (2005) Mechanisms of neurotransmitter release by amphetamines: A review. Prog. Neurobiol. 75, 406-433
10. --coupled neurotransmitter transporters: Why amphetamines take two to tango. J. Neurochem. 112, 340-355
11. Johnson, L. A., Guptaroy, B., Lund, D., Shamban, S., and Gnegy, M. E. (2005) Regulation of amphetamine-stimulated dopamine efflux by protein kinase Cβ. J. Biol. Chem. 280, 10914-10919
12. Chen, R., Furman, C. A., Zhang, M., Kim, M. N., Gereau, R. W., 4th, Leitges, M., and Gnegy, M. E. (2009) Protein kinase Cβ is a critical regulator of dopamine transporter trafficking and regulates the behavioral response to amphetamine in mice. J. Pharmacol. Exp. Ther. 328, 912-920
13. Fog, J. U., Khoshbouei, H., Holy, M., Owens, W. A., Vaegter, C. B., Sen, N., Nikandrova, Y., Bowton, E., McMahon, D. G., Colbran, R. J., Daws, L. C., Sitte, H. H., Javitch, J. A., Galli, A., and Gether, U. (2006) Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport. Neuron 51, 417-429
14. Mabb, A. M., Judson, M. C., Zylka, M. J., and Philpot, B. D. (2011) Angelman syndrome: Insights into genomic imprinting and neurodevelopmental phenotypes. Trends Neurosci. 34, 293-303
15. Jiang, Y. H., Armstrong, D., Albrecht, U., Atkins, C. M., Noebels, J. L., Eichele, G., Sweatt, J. D., and Beaudet, A. L. (1998) Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long term potentiation. Neuron 21, 799-811
16. Weeber, E. J., Jiang, Y. H., Elgersma, Y., Varga, A. W., Carrasquillo, Y., Brown, S. E., Christian, J. M., Mirnikjoo, B., Silva, A., Beaudet, A. L., and Sweatt, J. D. (2003) Derangements of hippocampal calcium/calmodulin- dependent protein kinase II in a mouse model for Angelman mental retardation syndrome. J. Neurosci. 23, 2634-2644
17. Elgersma, Y., Fedorov, N. B., Ikonen, S., Choi, E. S., Elgersma, M., Carvalho, O. M., Giese, K. P., and Silva, A. J. (2002) Inhibitory autophosphorylation of CaMKII controls PSD association, plasticity, and learning. Neuron 36, 493-505
18. Rayport, S., Sulzer, D., Shi, W. X., Sawasdikosol, S., Monaco, J., Batson, D., and Rajendran, G. (1992) Identified postnatal mesolimbic dopamine neurons in culture: Morphology and electrophysiology. J. Neurosci. 12, 4264-4280
19. Sucic, S., Dallinger, S., Zdrazil, B., Weissensteiner, R., Jørgensen, T. N., Holy, M., Kudlacek, O., Seidel, S., Cha, J. H., Gether, U., Newman, A. H., Ecker, G. F., Freissmuth, M., and Sitte, H. H. (2010) The N terminus of monoamine transporters is a lever required for the action of amphetamines. J. Biol. Chem. 285, 10924-10938
20. Scholze, P., Sitte, H. H., and Singer, E. A. (2001) Substantial loss of substrate by diffusion during uptake in HEK-293 cells expressing neurotransmitter transporters. Neurosci. Lett. 309, 173-176
21. 2+/calmodulin-dependent protein kinase II. A re-evaluation of inhibitor studies. Biochem. Pharmacol. 60, 1655-1663
22. van Woerden, G. M., Harris, K. D., Hojjati, M. R., Gustin, R. M., Qiu, S., de Avila Freire, R., Jiang, Y. H., Elgersma, Y., and Weeber, E. J. (2007) Rescue of neurological deficits in a mouse model for Angelman syndrome by reduction of αCaMKII inhibitory phosphorylation. Nat. Neurosci. 10, 280-282
23. Falkenburger, B. H., Barstow, K. L., and Mintz, I. M. (2001) Dendrodendritic inhibition through reversal of dopamine transport. Science 293, 2465-2470
24. Albrecht, U., Sutcliffe, J. S., Cattanach, B. M., Beechey, C. V., Armstrong, D., Eichele, G., and Beaudet, A. L. (1997) Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons. Nat. Genet. 17, 75-78
25. Elgersma, Y., Sweatt, J. D., and Giese, K. P. (2004) Mouse genetic approaches to investigating calcium/calmodulin-dependent protein kinase II function in plasticity and cognition. J. Neurosci. 24, 8410-8415
26. Williams, C. A. (2010) The behavioral phenotype of the Angelman syndrome. Am. J. Med. Genet. C Semin. Med. Genet. 154C, 432-437
27. Clayton-Smith, J., and Laan, L. (2003) Angelman syndrome: A review of the clinical and genetic aspects. J. Med. Genet. 40, 87-95
28. Huang, H. S., Allen, J. A., Mabb, A. M., King, I. F., Miriyala, J., Taylor-Blake, B., Sciaky, N., Dutton, J. W., Jr., Lee, H. M., Chen, X., Jin, J., Bridges, A. S., Zylka, M. J., Roth, B. L., and Philpot, B. D. (2012) Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature 481, 185-189
29. 2+/calmodulin- dependent kinase II-dependent mechanism. Mol. Pharmacol. 71, 835-842
30. Quick, M. W. (2006) The role of SNARE proteins in trafficking and function of neurotransmitter transporters. Handb. Exp. Pharmacol. 181-196
31. Binda, F., Dipace, C., Bowton, E., Robertson, S. D., Lute, B. J., Fog, J. U., Zhang, M., Sen, N., Colbran, R. J., Gnegy, M. E., Gether, U., Javitch, J. A., Erreger, K., and Galli, A. (2008) Syntaxin 1A interaction with the dopamine transporter promotes amphetamine-induced dopamine efflux. Mol. Pharmacol. 74, 1101-1108
32. Hornykiewicz, O. (2006) The discovery of dopamine deficiency in the parkinsonian brain. J. Neural Transm. Suppl. 70, 9-15
33. Nakamura, K., Sekine, Y., Ouchi, Y., Tsujii, M., Yoshikawa, E., Futatsubashi, M., Tsuchiya, K. J., Sugihara, G., Iwata, Y., Suzuki, K., Matsuzaki, H., Suda, S., Sugiyama, T., Takei, N., and Mori, N. (2010) Brain serotonin and dopamine transporter bindings in adults with high-functioning autism. Arch. Gen. Psychiatry 67, 59-68
34. Mazei-Robison, M. S., Bowton, E., Holy, M., Schmudermaier, M., Freissmuth, M., Sitte, H. H., Galli, A., and Blakely, R. D. (2008) Anomalous dopamine release associated with a human dopamine transporter coding variant. J. Neurosci. 28, 7040-7046
35. Bolan, E. A., Kivell, B., Jaligam, V., Oz, M., Jayanthi, L. D., Han, Y., Sen, N., Urizar, E., Gomes, I., Devi, L. A., Ramamoorthy, S., Javitch, J. A., Zapata, A., and Shippenberg, T. S. (2007) D2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3-kinase-independent mechanism. Mol. Pharmacol. 71, 1222-1232
36. Bowton, E., Saunders, C., Erreger, K., Sakrikar, D., Matthies, H. J., Sen, N., Jessen, T., Colbran, R. J., Caron, M. G., Javitch, J. A., Blakely, R. D., and Galli, A. (2010) Dysregulation of dopamine transporters via dopamine D2 autoreceptors triggers anomalous dopamine efflux associated with attention-deficit hyperactivity disorder. J. Neurosci. 30, 6048-6057
37. Williams, J. M., Owens, W. A., Turner, G. H., Saunders, C., Dipace, C., Blakely, R. D., France, C. P., Gore, J. C., Daws, L. C., Avison, M. J., and Galli, A. (2007) Hypoinsulinemia regulates amphetamine-induced reverse transport of dopamine. PLoS Biol. 5, e274
38. Owens, W. A., Williams, J. M., Saunders, C., Avison, M. J., Galli, A., and Daws, L. C. (2012) Rescue of dopamine transporter function in hypoinsulinemic rats by a D2 receptor-ERK-dependent mechanism. J. Neurosci. 32, 2637-2647
39. Mulherkar, S. A., and Jana, N. R. (2010) Loss of dopaminergic neurons and resulting behavioural deficits in mouse model of Angelman syndrome. Neurobiol. Dis. 40, 586-592
40. Harbord, M. (2001) Levodopa responsive Parkinsonism in adults with Angelman syndrome. J. Clin. Neurosci. 8, 421-422